Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Imugene ( (AU:IMU) ) is now available.
Imugene Limited has announced a proposed issue of securities under a securities purchase plan, which includes the issuance of new quoted options and ordinary fully paid shares. This strategic move is aimed at bolstering the company’s financial position and supporting its ongoing research and development efforts in cancer immunotherapy, potentially enhancing its market position and offering value to its stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of innovative immunotherapies for cancer treatment. The company is committed to advancing its pipeline of products to address unmet needs in oncology, aiming to improve patient outcomes through cutting-edge scientific research and development.
Average Trading Volume: 558,515
Technical Sentiment Signal: Sell
Current Market Cap: A$93.35M
See more insights into IMU stock on TipRanks’ Stock Analysis page.